Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Mentholatum Australasia is a prominent health and wellness company specializing in the development and distribution of over-the-counter (OTC) pharmaceuticals and therapeutic skincare products. As a subsidiary of the Japanese global giant Rohto Pharmaceutical, the company manages a portfolio of iconic brands such as Deep Heat, Ice Gel, and Rohto Eye Drops. Their product range addresses diverse consumer needs including topical pain relief, eye care, and medicated skincare for conditions like acne. The company maintains a Therapeutic Goods Administration (TGA) licensed manufacturing facility in Victoria, ensuring high-quality production standards for the Australasian market. Mentholatum Australasia continues to expand its presence through innovation in topical delivery systems and strategic brand management.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Mentholatum Australasia.